Xavier Matias-Guiu Guia
Degree: PhD
973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: http://www.researcherid.com/rid/C-3039-2009
Groups
Publications
-
Santiago-O'Farrill, JM; Weroha, SJ; Hou, XN; Oberg, AL; Heinzen, EP; Maurer, MJ; Pang, L; Rask, P; Amaravadi, RK; Becker, SE; Romero, I; Rubio, MJ; Matias-Guiu, X; Santacana, M; Llombart-Cussac, A; Poveda, A; Lu, Z; Bast, RC
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
CANCER 126 894-907. .
-
Palacios J; de la Hoya M; Bellosillo B; de Juan I; Matías-Guiu X; Lázaro C; Palanca S; Osorio A; Rojo F; Rosa-Rosa JM; Cigudosa JC
Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
VIRCHOWS ARCHIV 476 195-207. .
-
Cuevas, D; Velasco, A; Vaquero, M; Santacana, M; Gatius, S; Eritja, N; Estaran, E; Matias-Guiu, X
Intratumor heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification (MLPA). A DESCRIPTIVE STUDY.
Histopathology 76 447-460. .
-
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet, X; Matias-Guiu, X; Marti, RM; Macia, A
T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF V600E melanoma: TTCCs are therapy target in BRAF V600E melanoma.
JOURNAL OF INVESTIGATIVE DERMATOLOGY 140 1253-1265. .
-
Davidson, B; Matias-Guiu, X; Lax, SF
The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma.
VIRCHOWS ARCHIV 476 489-490. .
-
Cameselle-Teijeiro JM; Bella Cueto MR; Eloy C; Abdulkader I; Amendoeira I; Matías-Guiu X; Sobrinho-Simões M
Tumores de la glándula tiroides. Propuesta para el manejo y estudio de las muestras de pacientes con neoplasias tiroideas.
REVISTA ESPANOLA DE PATOLOGIA 53 27-36. .
-
Etxeberria, I; Bolaños E; Quetglas, JI; Gros, A; Villanueva, A; Palomero, J; Sanchez-Paulete, AR; Piulats, JM; Matias-Guiu, X; Olivera, I; Ochoa, MC; Labiano, S; Garasa, S; Rodriguez, I; Vidal, A; Mancheño U; Hervas-Stubbs, S; Azpilikueta, A; Otano, I; Aznar, MA; Sanmamed, MF; Inoges, S; Berraondo, P; Teijeira, A; Melero, I
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8(+)T Cells
CANCER CELL 36 613-629. .
-
Capdevila, J; Mayor, R; Mancuso, FM; Iglesias, C; Caratu, G; Matos, I; Zafon, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, JM; Alvarez, CV; Recio, JA; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J
Early evolutionary divergence between papillary and anaplastic thyroid cancers (vol 29, pg 1454, 2018)
ANNALS OF ONCOLOGY 30 1843-1843. .
-
Roman-Canal, B; Moiola, CP; Gatius, S; Bonnin, S; Ruiz-Miro, M; Gonzalez, E; Ojanguren, A; Recuero, JL; Gil-Moreno, A; Falcon-Perez, JM; Ponomarenko, J; Porcel, JM; Matias-Guiu, X; Colas, E
EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer
SCIENTIFIC REPORTS 9 15057-15057. .
-
Palacios, Jose; Matias-Guiu, Xavier; Rodriguez-Peralto, Jose Luis; de Alava, Enrique; Lopez, Jose Ignacio
Retos e implicaciones clínicas de la heterogeneidad intratumoral
REVISTA ESPANOLA DE PATOLOGIA 52 234-241. .
-
Majem, B; Parrilla, A; Jimenez, C; Suarez-Cabrera, L; Barber, M; Marin, A; Castellvi, J; Tamayo, G; Moreno-Bueno, G; Ponce, J; Matias-Guiu, X; Alameda, F; Romero, I; Sanchez, JL; Perez-Benavente, A; Moran, S; Esteller, M; Reventos, J; Rigau, M; Gil-Moreno, A; Segura, MF; Santamaria, A
MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways
ONCOGENE 38 6035-6050. .
-
Visser NCM; van der Putten LJM; van Egerschot, A; Van de Vijver, KK; Santacana, M; Bronsert, P; Hirschfeld, M; Colas, E; Gil-Moreno, A; Garcia, A; Mancebo, G; Alameda, F; Krakstad, C; Tangen, IL; Huvila, J; Schrauwen, S; Koskas, M; Walker, F; Weinberger, V; Minar, L; Hausnerova, J; Snijders MPLM; van den Berg-van Erp, S; Matias-Guiu, X; Trovik, J; Amant, F; Massuger LFAG; Bulten, J; Pijnenborg JMA
Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
HUMAN PATHOLOGY 89 90-98. .
Projects
- Unravelling the molecular and phenotypic complexity of endometriosis through new models and omics integration: towards a personalized clinical management
- Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
- EPH Receptor Signaling in Endometrial Cancer
- Ajuts per a la contractació de personal investigador novell (FI)
- Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
- "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
- EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
- Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
- CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
- DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
- Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
- VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU
